When Rachel Archer noticed a small pimple on her forehead, she thought nothing of it—having acne-prone skin, she was used to ...

At just 52 years old, a woman has been diagnosed with Stage 4 lung cancer. A non-smoker who had worked full-time since age 22 ...

New research reveals that combining lurbinectedin with atezolizumab significantly improves survival rates for patients with ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for certain cancers as well as immunotherapies that are breaking new ground by ...

Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have improved survival following immunotherapy compared to patients without ...

Cancer is not a welcome diagnosis, but breakthroughs in genetic sequencing and immunotherapy are making some cancers easier ...

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...

The majority of patients with the most common advanced or metastatic cancers in the United States do not undergo ...

Results of a meta-analysis suggest that ctDNA positivity is a “biomarker for poor postoperative recurrence and survival outcomes in NSCLC patients,” researchers wrote.

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Anlotinib combined with immune checkpoint inhibitors may benefit patients with extensive-stage small cell lung cancer treated ...

CHEST guideline updates support minimally invasive resection and targeted therapy to enhance survival in Stage I–II NSCLC.